Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial

2017, Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study, Lancet Gastroenterol Hepatol, 2, 161, 10.1016/S2468-1253(16)30181-9 Berto, 2017, Current challenges and possible solutions to improve access to care and treatment for hepatitis C infection in Vietnam: a systematic review, BMC Infect Dis, 17, 260, 10.1186/s12879-017-2360-6 Chen, 2017, Hepatitis C virus genotypes and subtypes circulating in Mainland China, Emerg Microbes Infect, 6, e95, 10.1038/emi.2017.77 Gower, 2014, Global epidemiology and genotype distribution of the hepatitis C virus infection, J Hepatol, 61, S45, 10.1016/j.jhep.2014.07.027 Lim, 2016, Time for action on viral hepatitis, Ann Acad Med Singapore, 45, 27, 10.47102/annals-acadmedsg.V45N1p27 McDonald, 2015, Projections of the current and future disease burden of hepatitis C virus infection in Malaysia, PLoS One, 10, e0128091, 10.1371/journal.pone.0128091 Wasitthankasem, 2015, Genotypic distribution of hepatitis C virus in Thailand and Southeast Asia, PLoS One, 10, e0126764, 10.1371/journal.pone.0126764 2017 Feld, 2015, Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection, N Engl J Med, 373, 2599, 10.1056/NEJMoa1512610 Foster, 2015, Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection, N Engl J Med, 373, 2608, 10.1056/NEJMoa1512612 Clopper, 1934, The use of confidence or fiducial limits illustrated in the case of the binomial, Biometrika, 26, 404, 10.1093/biomet/26.4.404 Jacobson, 2015, High efficacy of sofosbuvir/velpatasvir across 7 HCV genotypes and 46 subtypes: pooled data from the ASTRAL1, 2 and 3 Trials Lim, 2018, Findings from a large Asian chronic hepatitis C real-life study, J Viral Hepat, 25, 1533, 10.1111/jvh.12989 Wei, 2017 Rao, 2014, Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection, J Gastroenterol Hepatol, 29, 545, 10.1111/jgh.12398 Esteban, 2018, Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis, Gastroenterology, 155, 1120, 10.1053/j.gastro.2018.06.042 Jacobson, 2017, Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials, Gastroenterology, 153, 113, 10.1053/j.gastro.2017.03.047 von Felden, 2018, High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection, Aliment Pharmacol Ther, 47, 1288, 10.1111/apt.14592 Welzel, 2017, Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses, J Hepatol, 67, 224, 10.1016/j.jhep.2017.03.014 Curry, 2015, Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis, N Engl J Med, 373, 2618, 10.1056/NEJMoa1512614 2018, EASL recommendations on treatment of hepatitis C 2018, J Hepatol, 69, 461, 10.1016/j.jhep.2018.03.026 2015, Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus, Hepatology, 62, 932, 10.1002/hep.27950 Omata, 2016, APASL consensus statements and recommendation on treatment of hepatitis C, Hepatol Int, 10, 702, 10.1007/s12072-016-9717-6